By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Adgero Biopharmaceuticals Holdings, Inc. 

4365 US 1 South
Suite 211
Princeton  New Jersey  08540  U.S.A.
Phone: 609-917-9796 Fax: 609-356-0065


SEARCH JOBS

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer ("CMBC"), who had previously received chemotherapy and failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

YEAR FOUNDED:

2012

LEADERSHIP:

CEO: Frank Pilkiewicz

CFO: Jane M. Maida

JOBS:

Please click here for Adgero job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Private

Web Site: Adgero Biopharmaceuticals Holdings, Inc.
Employees:
Symbol: 
 









Company News
//-->